Characteristics of patients at HSCT
| . | Overall . | TCRαβ/CD19 . | PTCY . | P value . |
|---|---|---|---|---|
| n | 64 | 40 | 24 | |
| Male, n (%) | 53 (83) | 35 (88) | 18 (75.0) | .347 |
| Age at diagnosis, mean (SD), y | 2.31 (3.1) | 2.38 (3.3) | 2.21 (2.8) | .836 |
| Inheritance mode, n (%) | .141 | |||
| Autosomal recessive proven | 18 (28.1) | 11 (27.5) | 7 (29.2) | |
| Unknown | 2 (3.1) | 0 (0.0) | 2 (8.3) | |
| X-linked proven | 43 (67.2) | 29 (72.5) | 14 (58.3) | |
| X-linked suspected | 1 (1.6) | 0 (0.0) | 1 (4.2) | |
| Infection <6 mo before HSCT, n (%) | 29 (45) | 15 (38) | 14 (58) | .173 |
| Status of infection at HSCT, n (%) | .029 | |||
| CR under specific treamtent | 24 (66.7) | 14 (70.0) | 10 (62.5) | |
| CR without specific treamtent | 5 (13.9) | 5 (25.0) | 0 (0.0) | |
| PR under specific treatment | 6 (16.7) | 1 (5.0) | 5 (31.2) | |
| Unknown | 1 (2.8) | 0 (0.0) | 1 (6.2) | |
| Inflammation before HSCT, n (%) | 44 (67) | 26 (65.0) | 18 (75.0) | .577 |
| Colitis | 23 (36) | 11 (28) | 12 (50.0) | .122 |
| Lung inflammation | 25 (39) | 17 (43) | 8 (33) | .643 |
| Immunosuppressive drugs at HSCT, n (%) | 24 (38) | 11 (28) | 13 (54) | .062 |
| Status of inflammation at HSCT, n (%) | ||||
| Not active | 54 (84.4) | 34 (85.0) | 20 (83.3) | 1 |
| Active | 10 (15.6) | 6 (15.0) | 4 (16.7) | |
| Reason for HSCT, n (%) | .177 | |||
| Severity of infection(s) | 27 (42.2) | 21 (52.5) | 6 (25.0) | |
| Both severity of inflammation and infection(s) | 19 (29.7) | 10 (25.0) | 9 (37.5) | |
| Severity of inflammation | 11 (17.2) | 5 (12.5) | 6 (25.0) | |
| Elective | 7 (10.9) | 4 (10.0) | 3 (12.5) |
| . | Overall . | TCRαβ/CD19 . | PTCY . | P value . |
|---|---|---|---|---|
| n | 64 | 40 | 24 | |
| Male, n (%) | 53 (83) | 35 (88) | 18 (75.0) | .347 |
| Age at diagnosis, mean (SD), y | 2.31 (3.1) | 2.38 (3.3) | 2.21 (2.8) | .836 |
| Inheritance mode, n (%) | .141 | |||
| Autosomal recessive proven | 18 (28.1) | 11 (27.5) | 7 (29.2) | |
| Unknown | 2 (3.1) | 0 (0.0) | 2 (8.3) | |
| X-linked proven | 43 (67.2) | 29 (72.5) | 14 (58.3) | |
| X-linked suspected | 1 (1.6) | 0 (0.0) | 1 (4.2) | |
| Infection <6 mo before HSCT, n (%) | 29 (45) | 15 (38) | 14 (58) | .173 |
| Status of infection at HSCT, n (%) | .029 | |||
| CR under specific treamtent | 24 (66.7) | 14 (70.0) | 10 (62.5) | |
| CR without specific treamtent | 5 (13.9) | 5 (25.0) | 0 (0.0) | |
| PR under specific treatment | 6 (16.7) | 1 (5.0) | 5 (31.2) | |
| Unknown | 1 (2.8) | 0 (0.0) | 1 (6.2) | |
| Inflammation before HSCT, n (%) | 44 (67) | 26 (65.0) | 18 (75.0) | .577 |
| Colitis | 23 (36) | 11 (28) | 12 (50.0) | .122 |
| Lung inflammation | 25 (39) | 17 (43) | 8 (33) | .643 |
| Immunosuppressive drugs at HSCT, n (%) | 24 (38) | 11 (28) | 13 (54) | .062 |
| Status of inflammation at HSCT, n (%) | ||||
| Not active | 54 (84.4) | 34 (85.0) | 20 (83.3) | 1 |
| Active | 10 (15.6) | 6 (15.0) | 4 (16.7) | |
| Reason for HSCT, n (%) | .177 | |||
| Severity of infection(s) | 27 (42.2) | 21 (52.5) | 6 (25.0) | |
| Both severity of inflammation and infection(s) | 19 (29.7) | 10 (25.0) | 9 (37.5) | |
| Severity of inflammation | 11 (17.2) | 5 (12.5) | 6 (25.0) | |
| Elective | 7 (10.9) | 4 (10.0) | 3 (12.5) |
CR, complete remission; HSCT, hematopoietic stem-cell transplantation; PR, partial remission; SD, standard deviation.
Boldface P values are statistically significant (P < .05).